Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder. More: Akcea’s rare lipid disorder drug wins PIM status
read moreFrench biotech GamaMabs Pharma has licensed technology owned by AstraZeneca’s MedImmune to research and produce a novel antibody-drug conjugate (ADC) to treat cancer. More: GamaMabs licences AZ technology for new cancer therapy Source: News
read moreAstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway. More: AZ’ lung cancer drug Tagrisso bags breakthrough
read morePatients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa. More: Darzalex, Epclusa will
read moreIn the last three months, budding CDMO Avara Pharmaceutical Services has bought three plants from Big Pharma. It acquired a Pfizer sterile injectables facility in August, a GlaxoSmithKline consumer plant in September and has now picked up a solid dose
read moreWith one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish drugmaker has filed a citizen petition arguing Victoza’s manufacturing
read more© 1994 - 2026 B.M. Pharmaceuticals